Jagsonpal Pharmaceuticals Ltd vs Jfl Life Sciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Jagsonpal Pharmaceuticals Ltd is ₹ 206.8 as of 05 May 15:30 . The P/E Ratio of Jagsonpal Pharmaceuticals Ltd changed from 12.2 on March 2021 to 25.9 on March 2025 . This represents a CAGR of 16.25% over 5 yearsThe P/E Ratio of JFL Life Sciences Ltd changed from 12.9 on March 2023 to 13.9 on March 2025 . This represents a CAGR of 2.52% over 3 years The Market Cap of Jagsonpal Pharmaceuticals Ltd changed from ₹ 208.41 crore on March 2021 to ₹ 1433 crore on March 2025 . This represents a CAGR of 47.06% over 5 yearsThe Market Cap of JFL Life Sciences Ltd changed from ₹ 36.29 crore on March 2023 to ₹ 57.58 crore on March 2025 . This represents a CAGR of 16.63% over 3 years The revenue of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 67.37 crore as compare to the Dec '25 revenue of ₹ 75.92 crore. This represent the decline of -11.26% The revenue of JFL Life Sciences Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 26.85 crore. This represent the decline of -100% The ebitda of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 14.33 crore as compare to the Dec '25 ebitda of ₹ 17.16 crore. This represent the decline of -16.49% The ebitda of JFL Life Sciences Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 3.36 crore. This represent the decline of -100% The net profit of Jagsonpal Pharmaceuticals Ltd changed from ₹ 5.33 crore to ₹ 8.76 crore over 8 quarters. This represents a CAGR of 28.20% The net profit of JFL Life Sciences Ltd changed from ₹ 1.91 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Jagsonpal Pharmaceuticals Ltd changed from 15.36 % on March 2021 to 29.99 % on March 2025 . This represents a CAGR of 14.32% over 5 yearsThe Dividend Payout of JFL Life Sciences Ltd changed from 8.33 % on March 2024 to 0 % on March 2025 . This represents a CAGR of -100.00% over 2 years .

About Jagsonpal Pharmaceuticals Ltd

Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana.
The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs.
Simultaneously, it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India.
It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product.
In 1994, the company has also promoted Aresco Financial Services, a new financial company.

About JFL Life Sciences Ltd

JFL Life Sciences Limited was incorporated as JFL Life Sciences Private Limited' on April 25, 2010 as a Private Limited Company.
Pursuant to a Special Resolution held on February 10, 2022, Company converted from a Private Limited to Public Limited Company and name of the Company was changed to JFL Life Sciences Limited', on March 3, 2022.
The Company manufactures and market pharmaceutical products.
The major products are Dry powder injections, Tablets & Capsules (B-Lactam) solid oral dosage form, Tablet and capsules (General) and Oral Rehydration Solutions (ORS). In August 2022, the Company launched an IPO of 29,78,000 Equity Shares by raising funds aggregating to Rs. 18.16 Crore. The Company export products to African countries, Middle Eastern countries and CIS countries, mainly through merchant exporters.

FAQs for the comparison of Jagsonpal Pharmaceuticals Ltd and JFL Life Sciences Ltd

Which company has a larger market capitalization, Jagsonpal Pharmaceuticals Ltd or JFL Life Sciences Ltd?

Market cap of Jagsonpal Pharmaceuticals Ltd is 1,425 Cr while Market cap of JFL Life Sciences Ltd is 59 Cr

What are the key factors driving the stock performance of Jagsonpal Pharmaceuticals Ltd and JFL Life Sciences Ltd?

The stock performance of Jagsonpal Pharmaceuticals Ltd and JFL Life Sciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Jagsonpal Pharmaceuticals Ltd and JFL Life Sciences Ltd?

As of May 5, 2026, the Jagsonpal Pharmaceuticals Ltd stock price is INR ₹212.25. On the other hand, JFL Life Sciences Ltd stock price is INR ₹8.95.

How do dividend payouts of Jagsonpal Pharmaceuticals Ltd and JFL Life Sciences Ltd compare?

To compare the dividend payouts of Jagsonpal Pharmaceuticals Ltd and JFL Life Sciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.